References of "WEEKERS, Laurent"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEtude clinique du mois. Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL
Weekers, Laurent ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2001), 56(10), 723-726

Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established ... [more ▼]

Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established nephroprotective effect in type 1 diabetic nephropathy, this remained to be shown for type 2 diabetes. Two large outcome trials using angiotensin II receptor antagonists (ARA's) in proteinuric chronic renal impairment and hypertensive type 2 diabetic patients have now closed this gap: the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) trial. Both trials showed a significant reduction in the primary pre-specified end-point of death, or worsening of renal function (doubling of serum creatinine) or the development of end-stage renal disease. This effect goes beyond the reduction in blood pressure and makes of ARA's one of the important tools in the treatment of type 2 diabetic nephropathy. [less ▲]

Detailed reference viewed: 137 (1 ULg)
Peer Reviewed
See detailL'etude clinique du mois. L'etude CALM ou interet de combiner un inhibiteur de l'enzyme de conversion et un antagoniste du recepteur de type 1 de l'angiotensine II dans le traitement de la nephropathie diabetique.
Philips, Jean-Christophe ULg; Weekers, Laurent ULg; Scheen, André ULg

in Revue Médicale de Liège (2001), 56(2), 126-8

The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme ... [more ▼]

The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria. The study included 200 patients randomized to receive candesartan 16 mg or lisinopril 20 mg for 12 weeks, followed by 12 weeks of the same monotherapy or a combination treatment. Main outcomes are the reduction of microalbuminuria and blood pressure. All three of the treatments are effective, but the dual blockade is respectively 18%, 8 mmHg and 5 mmHg more effective in reducing microalbuminuria, systolic and diastolic blood pressure. No comparison is made between this "new" association and the more frequently used biotherapy (i.e. ACE-I plus thiazidic diuretic) and therefore its usefulness in regular practice is still to be determined. [less ▲]

Detailed reference viewed: 107 (0 ULg)
Peer Reviewed
See detailRenal response to increasing doses of angiotensin converting enzyme inhibitor (ACEI) in type 1 diabetes mellitus according to ACE I/D polymorphism
Weekers, Laurent ULg; Bouhanick, Béatrice; Gallois, Yves et al

in Nephrology Dialysis Transplantation (2001), 16(6), 7

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailGénétique de la Néphropathie diabétique
Hadjadj, Samy; Weekers, Laurent ULg; Marre, Michel

in Sang Thrombose Vaisseaux [=STV] (2000), 12(3), 151-156

Detailed reference viewed: 19 (4 ULg)
Peer Reviewed
See detailRecommandations a propos du traitement de l'hypertension arterielle chez le patient diabetique.
Scheen, André ULg; Rorive, Marcelle ULg; Estrella, F. et al

in Revue Médicale de Liège (2000), 55(5), 376-82

Diabetes mellitus is frequently associated with arterial hypertension and the combination of the two entities markedly increases the cardiovascular risk and accelerates the progression of microangiopathy ... [more ▼]

Diabetes mellitus is frequently associated with arterial hypertension and the combination of the two entities markedly increases the cardiovascular risk and accelerates the progression of microangiopathy (more particularly nephropathy) in both type 1 and type 2 diabetic patients. Numerous international guidelines have been published during the last few years to help the practitioner in targeting ideal arterial blood pressure levels (lower in diabetic than in non-diabetic patients) and in selecting first-choice antihypertensive agents. We will concisely summarize the main messages of these recommendations and insist upon the persistence of uncertainties, or even the existence of inconsistencies, more particularly regarding preferential indications of antihypertensive agents in diabetic patients. [less ▲]

Detailed reference viewed: 58 (1 ULg)
Peer Reviewed
See detailGenetic polymorphism of transforming growth factor-β1 and microvascular complications in type 1 diabetes
Weekers, Laurent ULg; Hadjadj, Samy; Bouhanick, Béatrice et al

in Diabetologia (2000), 43(1), 137

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailRelationship between incipiens nephropathy and cardiac autonomic neuropathy in type 1 diabetes
Estrella, Frederico; Scheen, André ULg; Marchand, Monique et al

in Diabetes (2000), 49(sup. 1), 379-380

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailLa variation de l’équilibre glycémique (mais pas du poids) est corrélée positivement à la modification du risque cardiovasculaire absolu chez le patient diabétique
Hadjadj, Samy; Guilloteau, Gérard; Weekers, Laurent ULg et al

in Archives des Maladies du Coeur et des Vaisseaux (2000), 93(8), 1033-1036

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailIron monitoring under vitamin C therapy in hemodialysed patients treated with erythropoietin
Bovy, Christophe ULg; Dubois, Bernard ULg; Weekers, Laurent ULg et al

in Nephrology Dialysis Transplantation (2000), 15(9), 156

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailGenetic polymorphism of transforming growth factor-β1 and microvascular complications in type 1 diabetes
Weekers, Laurent ULg; Hadjadj, S.; Bouhanick, B. et al

Conference (2000)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailWhat do the needles, syringes, lancets and reagent strips of diabetic patients become in the absence of a common attitude? About 1070 questionnaires in diabetic clinics.
Bouhanick, B.; Hadjadj, S.; Weekers, Laurent ULg

in Diabètes & Métabolism (2000), 26(4), 288-93

The aim was to investigate the fate of injection and monitoring material after its use by diabetic patients in different countries (France, Belgium, Luxemburg, Switzeland and Tunisia). Some suitable ... [more ▼]

The aim was to investigate the fate of injection and monitoring material after its use by diabetic patients in different countries (France, Belgium, Luxemburg, Switzeland and Tunisia). Some suitable containers are available for disposal but little is known about the attitudes of patients and physicians to them. 1 070 questionnaires were completed by patients (age: 50 +/- 18 years; diabetes duration: 15 +/- 11 years; 2.8 +/- 1.1 injections per day) visiting 109 doctors. Injections were done at home (72.6%), or both at home and at work (26.6%). At home: needles, syringes, lancets and reagent strips were thrown directly into the bin in 46.9%, 49.9%, 52.2% and 67.6% of cases, respectively; and in a closed plastic bottle in 29. 6%, 28.5%, 28.9% and 19.9% of cases, respectively. Specific containers were used in 8.6% and 6.3% of cases for needles and syringes, respectively. 62% of the bottles and containers were thrown directly into the bin, whereas 15.5% were returned to a pharmacy (4.5% taken to hospitals, 2.9% were burned). At work: 63% of the patients brought their needles and syringes home for disposal, 6.9% kept suitable containers at work and 30% threw their materials directly into local bins. We conclude that awareness should be increased and the organization of the collection of used material improved. [less ▲]

Detailed reference viewed: 22 (0 ULg)
Peer Reviewed
See detailHypertension arterielle et diabete de type 2.
Scheen, André ULg; Estrella, F.; Weekers, Laurent ULg

in Revue Médicale de Liège (1999), 54(10), 789-95

Diabetes mellitus is frequently associated with arterial hypertension and the combination of both entities markedly increases the vascular risk. In type 2 diabetes, hypertension appears very early ... [more ▼]

Diabetes mellitus is frequently associated with arterial hypertension and the combination of both entities markedly increases the vascular risk. In type 2 diabetes, hypertension appears very early, especially in the presence of obesity, is part of the insulin resistance syndrome, and contributes to high cardiovascular morbidity and mortality rates in this population. Appropriate regulation of blood pressure is crucial in order to reduce not only microangiopathy (nephropathy and retinopathy) but also macroangiopathy (coronary heart disease and stroke) in hypertensive type 2 diabetic patients. Target blood pressure values have been decreased in recent years and should be < 130/85 mmHg, and may be even lower according to recent data. The optimal modalities of pharmacological treatment remain controversial, but obviously several medications are required to reach such objectives in most hypertensive patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 85 (0 ULg)
Peer Reviewed
See detailLa variation de l’équilibre glycémique (mais pas du poids) est correlée positivement à la modification du risque cardio-vasculaire absolu chez le sujet diabétique
Hadjadj, Samy; Guilloteau, Gérard; Weekers, Laurent ULg et al

in Archives des Maladies du Coeur et des Vaisseaux (1999), 92

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailContribution de l'hypertension arterielle au risque vasculaire du diabetique.
Marre, M.; Bouhanick, B.; Hadjadj, S. et al

in Diabètes & Métabolism (1999), 25 Suppl 3

Hypertension is a major cardiovascular risk factor in diabetic subjects. Recent trials have suggested that blood pressure objectives should be < or = 140/80 mmHg. However, there is currently no evidence ... [more ▼]

Hypertension is a major cardiovascular risk factor in diabetic subjects. Recent trials have suggested that blood pressure objectives should be < or = 140/80 mmHg. However, there is currently no evidence supporting any particular preferential drug strategy for this treatment objective. [less ▲]

Detailed reference viewed: 20 (0 ULg)
Peer Reviewed
See detailLack of contribution of two endotelial nitric oxide synthase (eNOS) gene polymorphisms to diabetic nephropathy in type 1 diabetes
Weekers, Laurent ULg; Hadjadj, S.; Belloum, R. et al

in Diabetologia (1999), 42(Sup. 1), 226

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailComment j'explore ... la néphropathie diabétique. Deuxième partie: suivi de la filtration glomérulaire
Weekers, Laurent ULg; Scheen, André ULg; Godon, J. P.

in Revue Médicale de Liège (1998), 53(9), 571-5

The natural history of diabetic renal disease can be divided into different stages according to the degree of albuminuria and the level of glomerular filtration rate (GFR). Assessment of the early ... [more ▼]

The natural history of diabetic renal disease can be divided into different stages according to the degree of albuminuria and the level of glomerular filtration rate (GFR). Assessment of the early hyperfiltration state, as well as determination of the rate of decline in kidney function at a later stage require precise and accurate methods to measure GFR. In this article, we briefly remind the reader of the physiological basis of GFR. We then review the different techniques for the monitoring of kidney function (inulin clearance, endogenous creatinine clearance, plasma disappearance of a radiolabelled tracer) and discuss the pro and cons of each of them in different clinical settings. Finally, we try to define a rational use of these techniques in everyday clinical practice. [less ▲]

Detailed reference viewed: 53 (0 ULg)
Peer Reviewed
See detailComment j'explore ... la nephropathie diabetique. Premiere partie: micro- et macro-albuminurie.
Weekers, Laurent ULg; Scheen, André ULg; Lefebvre, Pierre ULg

in Revue Médicale de Liège (1998), 53(8), 494-8

Diabetic nephropathy (DN) appears in about 30% of patients with type 1 diabetes (D1) and 15 to 60% of patients with type 2 diabetes (D2). It is preceded by microalbuminuria. Microalbuminuria is defined as ... [more ▼]

Diabetic nephropathy (DN) appears in about 30% of patients with type 1 diabetes (D1) and 15 to 60% of patients with type 2 diabetes (D2). It is preceded by microalbuminuria. Microalbuminuria is defined as an albumin excretion rate between 30 and 300 mg/24 h (on a 24-hour urine collection) or between 20 and 200 micrograms/min (on an overnight collection) in at least two out of three consecutive collections made within a 6-month period. Alternative screening techniques use either dipstick (Micral-Test II) or the albumin to creatinine ratio on an early morning urine sample (30-300 mg/g creatinine). Once persistent microalbuminuria is confirmed, 80% of type 1 diabetic patients and 20 to 50% of type 2 diabetic patients will progress to DN. In D2, microalbuminuria also represents a powerful predictor of early mortality from cardiovascular disease. Macroalbuminuria (AER > 300 mg/24 h, corresponding to a total protein excretion > 500 mg/24 h) will eventually lead to a end-stage renal insufficiency within 10 to 20 years. In D2, numerous patients will die from cardiovascular disease before reaching end-stage renal failure. Angiotensin-converting enzyme inhibitors can slow down the evolution toward DN when prescribed when microalbuminuria appears. Screening for microalbuminuria should therefore be a part of the annual clinical assessment in every diabetic patient. [less ▲]

Detailed reference viewed: 76 (0 ULg)
Full Text
Peer Reviewed
See detailLa néphropathie épidémique a Hantavirus
Weekers, Laurent ULg; Biessaux, Yves ULg; Lamproye, Anne ULg et al

in Revue Médicale de Liège (1997), 52(8), 515-519

L'Entre-Sambre-et-Meuse a été le siège d'une épidémie de néphropathie épidémique à Hantavirus (NE) en 199293. Cinq cas ont été rencontrés au CHU de Liège en moins d'un an. Le virus responsable de cette ... [more ▼]

L'Entre-Sambre-et-Meuse a été le siège d'une épidémie de néphropathie épidémique à Hantavirus (NE) en 199293. Cinq cas ont été rencontrés au CHU de Liège en moins d'un an. Le virus responsable de cette affection appartient à la famille dès Hantavirus dont il existe huit sérotypes aux caractéristiques propres en terme de vecteur (rongeurs), de distribution géographique et de pathogénicité. Les pathologies induites chez l'homme vont de la néphropathie épidémique à Hantavirus - d'évolution le plus souvent bénigne- au syndrome pulmonaire à Hantavirus (SPH) - fréquemment mortel - en passant par la fièvre hémorragique avec syndrome rénal (FHSR) de sévérité intermédiaire. Dans nos contrées, on rencontre le sérotype Puumala dont le vecteur est le campagnol roussâtre. L'homme s'infecte par inhalation de particules contaminées et développe dans un pourcentage non précisé des cas, après une période d'incubation de 1 à 3 semaines, un tableau clinique de néphropathie épidémique à Hantavirus. Celui-ci se caractérise par l'apparition brutale d'une fièvre, de myalgies diffuses, de douleurs abdominales et/ou lombaires et de céphalées. Apparaissent ensuite à des degrés divers: nausées et vomissements, oligurie, myopie aiguë, toux,diathèse hémorragique, diarrhée... Biologiquement, on observe l'association d'une insuffisance rénale aiguë et d'une thrombopénie. L'évolution est spontanément favorable dans les deux à trois semaines. Le diagnostic suggéré par la clinique sera confirmé par la sérologie. La physiopathologie de l'insuffisance rénale et de la thrombopénie fait intervenir des interactions complexes entre l'hôte et le virus. Il n'existe pas de thérapeutique spécifique pour la néphropathie épidémique à Hantavirus. Les formes plus sévères (SPH et FHSR) peuvent bénéficierd'un traitement par Ribavirineen iv. [less ▲]

Detailed reference viewed: 71 (3 ULg)